INVA Stock Analysis: Buy, Sell, or Hold?
INVA - Innoviva, Inc. Common Stock
$21.70
0.35 (1.64%)
▲
5d:
-1.94%
30d:
-5.61%
90d:
-4.53%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When INVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: INVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.63
Based on 9.9% avg growth
INTRINSIC VALUE TODAY
$22.75
4.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INVA is currently trading at $21.70, which is considered oversold relative to its 30-day fair value range of $21.99 to $23.22. The stock's valuation (Forward PE: 9.8) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This pessimistic expectation contrasts with the company's recent 590.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INVA is in a uptrend. The price is currently testing key support at $21.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $35.50 (+63.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INVA is in a uptrend. The price is currently testing key support at $21.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $35.50 (+63.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.99 -
$23.22
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding INVA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.6% below Wall St target ($35.50)
Trading Range Analysis
30-Day Trading Range
$21.99 -
$23.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.24
Resistance Level
$22.95
Current Trend
Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.82
Wall Street Target
$35.50
(+63.6%)
Revenue Growth (YoY)
10.6%
Earnings Growth (YoY)
590.4%
Profit Margin
119.9%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
9.8 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$21.27
(-2%)
2-Year Target
$20.84
(-4%)
3-Year Target
$20.42
(-6%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$21.63
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 15.7%)
$75.01
(+246%)
Base:
(SPY PE: 9.8, Growth: 15.7%)
$33.62
(+55%)
Bear:
(PE: 8.3, Growth: 15.7%)
$28.57
(+32%)
📈
Valuation based on Current Earnings
Trailing PE: 3.54 | Current EPS (TTM): $6.26
Bull Case
$12.17
(-44%)
Analyst growth -50.0%, PE expands to 3.9
Base Case
$11.06
(-50%)
Market implied -50.0%, PE stable at 3.5
Bear Case
$15.05
(-31%)
Severe decline -20.0%, PE contracts to 3.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 10.4
Stabilization Target:
$22.98
(+5.9%)
PE Expansion Potential:
+5.9%
Share & Embed Analysis
Last updated: June 03, 2026 10:58 PM ET
Data refreshes hourly during market hours. Next update: 11:58 PM
Data refreshes hourly during market hours. Next update: 11:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
Advanced INVA Option Strategies
Professional options setups generated by AI based on today's INVA price and gamma walls.
